Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3529 Target Snapshot

Inhibitor of nuclear factor kappa-B kinase subunit epsilon · SINGLE PROTEIN · Homo sapiens

2,174Compounds
349Assays
12Approved Drugs
1,558.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q14164. Use UniProt Q14164 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q14164 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Inhibitor of nuclear factor kappa-B kinase subunit epsilon as ChEMBL target CHEMBL3529, mapped to UniProt Q14164. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Inhibitor of nuclear factor kappa-B kinase subunit epsilon
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3529
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q14164
Inhibitor of nuclear factor kappa-B kinase subunit epsilon
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Inhibitor of nuclear factor kappa-B kinase subunit epsilon is the right protein anchor across sources, using UniProt Q14164 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelInhibitor of nuclear factor kappa-B kinase subunit epsilon
UniProt AccessionQ14164
Component TypeProtein
Sequence Length716 aa

Inhibitor of nuclear factor kappa-B kinase subunit epsilon

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Inhibitor of nuclear factor kappa-B kinase subunit epsilon, mapped to UniProt Q14164. Sequence length is 716 aa.

Mapped IDQ14164
Review nameInhibitor of nuclear factor kappa-B kinase subunit epsilon
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

12
Approved
5
Phase III
12
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC50861.0
KI329.0
KD368.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.7 IC50 0.199 Preclinical
CHEMBL3682430 9.0 IC50 1.0 Preclinical
CHEMBL3687186 8.7 IC50 2.0 Preclinical
CHEMBL4537673 8.7 IC50 2.0 Preclinical
CHEMBL4566796 8.7 IC50 2.0 Preclinical
CHEMBL2011940 8.4 IC50 4.0 Preclinical
CHEMBL3682423 8.4 IC50 4.0 Preclinical
CHEMBL3682431 8.4 IC50 4.0 Preclinical
CHEMBL4436188 8.4 IC50 4.0 Preclinical
CHEMBL4454902 8.4 IC50 4.0 Preclinical
Distribution

pChEMBL Value Distribution

44
5.0
115
5.5
138
6.0
81
6.5
60
7.0
35
7.5
33
8.0
5
8.5
3
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
PACRITINIB
CHEMBL2035187
Approved 2022
FEDRATINIB
CHEMBL1287853
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

349
Total Assays
421
Tested Compounds
3
Assay Types
Binding — 346 assays, 421 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 260 315 6.5
assay format 32 36 7.2
cell-based format 31 36 5.6
subcellular format 23 34 6.1
Functional — 2 assays, 98 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 97 5.8
cell-based format 1 1 7.1
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine